Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Selective estrogen receptor modulator
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Available forms === {| class="wikitable sortable mw-collapsible <!--mw-collapsed-->" style="margin-left: auto; margin-right: auto; border: none;" |+ class="nowrap" | SERMs marketed for clinical or veterinary use |- ! Name !! Brand name !! Approved uses !! Launch !! Notes |- | [[Anordrin]] || Zi Yun || [[Emergency contraception]] || 1970s || Only in [[China]], combined with [[mifepristone]] |- | [[Bazedoxifene]] || Duavee || [[Osteoporosis]] prevention || 2013 || Combined with [[conjugated estrogens]] |- | [[Broparestrol]] || Acnestrol || [[Dermatology]]; [[Breast cancer]] treatment || 1970s || Discontinued |- | [[Clomifene]] || Clomid || [[Female infertility]] || 1967 || |- | [[Cyclofenil]] || Sexovid || Female infertility; [[Menopausal symptoms]] || 1970 || Mostly discontinued |- | [[Lasofoxifene]] || Fablyn || Osteoporosis prevention, treatment; [[Vaginal atrophy]] || 2009 || Only in [[Lithuania]] and [[Portugal]] |- | [[Ormeloxifene]] || Saheli || [[Hormonal contraception]] || 1991 || Only in [[India]] |- | [[Ospemifene]] || Osphena || [[Dyspareunia]] due to vaginal atrophy || 2013 || |- | [[Raloxifene]] || Evista || Osteoporosis prevention, treatment; Breast cancer prevention || 1997 || |- | [[Tamoxifen]] || Nolvadex || Breast cancer treatment || 1978 || |- | [[Toremifene]] || Fareston || Breast cancer treatment || 1997 || |- class="sortbottom" | colspan="5" style="width: 1px; background-color:#eaecf0; text-align: center;" | '''Sources:''' See individual articles. |}
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)